CTIS2022-500461-28-06招募中1 期
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer - I3Y-MC-JPEG
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 912
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- Male
入选标准
- •Prostate cancer that has spread to other parts of the body and is expected to respond to hormone treatments designed to lower testosterone (metastatic hormone-sensitive prostate cancer), Cancer that has spread to the bones significantly and/or to the viscera, which are the soft internal organs of the body (for example, the lungs, liver, and the organs of the digestive system)., Adequate organ function
排除标准
- •Received prior treatment with abemaciclib or other drugs that work in the same way, Received previous treatment(s) for metastatic cancer except for up to 3 months of androgen deprivation therapy (ADT) or up to 6 courses of chemotherapy with ADT, Serious or uncontrolled medical conditions such as certain cardiovascular disorders, active or chronic liver disease, uncontrolled hypertension, active systemic infections or currently treated for cancer other than prostate, Prostate cancer that has spread to the central nervous system that is not treated and stable
研究者
相似试验
进行中（未招募）
3 期
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)Prostatic NeoplasmsJPRN-jRCT2031220101Masaki Takeshi900
进行中（未招募）
1 期
A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia(VALOR) - VALOREUCTR2010-021961-61-ITSUNESIS PHARMACEUTICALS, INC.750
进行中（未招募）
1 期
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED, MULTI-CENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ADDED ON TO DICLOFENAC SR IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIPEUCTR2009-009318-41-FRPfizer Inc., 235 East 42nd Street, New York, NY 10017600
进行中（未招募）
不适用
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED, MULTI-CENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ADDED ON TO DICLOFENAC SR IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIPOsteoarthritis of the knee or hipMedDRA version: 9.1Level: LLTClassification code 10020108Term: Hips osteoarthritisMedDRA version: 9.1Level: LLTClassification code 10023476Term: Knee osteoarthritisEUCTR2009-009318-41-ATPfizer Inc., 235 East 42nd Street, New York, NY 10017600
进行中（未招募）
不适用
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED, MULTI-CENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ADDED ON TO DICLOFENAC SR IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIPEUCTR2009-009318-41-GBPfizer Inc., 235 East 42nd Street, New York, NY 10017600